Library

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis / R.N. de Nijs in The New England journal of medicine, 355(2006)7 ([08/17/2006])  

[article] Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [printed text] / R.N. de Nijs, Author ; J.W. Jacobs, Author ; W.F. Lems, Author ; R.F. Laan, Author ; A. Algra, Author ; A.M. Huisman, Author ; E. Buskens, Author ; Chris De Laet , Author . - 2006 . - 675-84. Languages : English (eng) in The New England journal of medicine > 355(2006)7 [08/17/2006] . - 675-84 Descriptors: Classification W 1 Serials. Periodicals Indexation Aged ; Bone Density ; Bone Diseases, Metabolic ; Double-Blind Method ; drug therapy ; Female ; Humans ; Journal Article ; Male ; Middle Aged ; Osteoporosis ; Peer Review ; Spine ; United States Abstract: BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration among patients with a rheumatic disease who were starting glucocorticoids at a daily dose that was equivalent to at least 7.5 mg of prednisone. A total of 201 patients were assigned to receive either alendronate (10 mg) and a placebo capsule of alfacalcidol daily or alfacalcidol (1 microg) and a placebo tablet of alendronate daily. The primary outcome was the change in bone mineral density of the lumbar spine in 18 months; the secondary outcome was the incidence of morphometric vertebral deformities. RESULTS: A total of 100 patients received alendronate, and 101 received alfacalcidol; 163 patients completed the study. The bone mineral density of the lumbar spine increased by 2.1 percent in the alendronate group (95 percent confidence interval, 1.1 to 3.1 percent) and decreased by 1.9 percent in the alfacalcidol group (95 percent confidence interval, -3.1 to -0.7 percent). At 18 months, the mean difference of change in bone mineral density between the two groups was 4.0 percent (95 percent confidence interval, 2.4 to 5.5 percent). Three patients in the alendronate group had a new vertebral deformity, as compared with eight patients in the alfacalcidol group (of whom three had symptomatic vertebral fractures) (hazard ratio, 0.4; 95 percent confidence interval, 0.1 to 1.4). CONCLUSIONS: During this 18-month trial in patients with rheumatic diseases, alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol. (ClinicalTrials.gov number, NCT00138983 [ClinicalTrials.gov].). Link for e-copy: http://www.nejm.org/doi/pdf/10.1056/NEJMoa053569 Format of e-copy: PDF [Open Access] (230 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2159 [article]

De behandeling van jicht / Ann Van den Bruel in Huisarts Nu, 33(2004)06 ([07/01/2004])  

[article] De behandeling van jicht : niet zo evident als het lijkt. Aanbevelingen als ondersteuning voor de huisarts [printed text] / Ann Van den Bruel, Author ; E. Vermeire, Author ; Bert Aertgeerts, Author ; F. Buntinx, Author . - 2004 . - 339-343. Languages : Dutch (dut) in Huisarts Nu > 33(2004)06 [07/01/2004] . - 339-343 Descriptors: Classification W 1 Serials. Periodicals Indexation Belgium ; drug therapy ; Evidence-Based Medicine ; Journal Article Abstract: Aanbevelingen zijn een goede ondersteuning in de praktijkvoering van de huisarts. In dit negende artikel van de PICO-reeks beoordelen de auteurs de waarde van de NHGStandaard Jicht in het beantwoorden van de vraag of colchicine een effectieve behandeling is voor acute jicht. Link for e-copy: http://www.domusmedica.be/onderzoek/huisartsnu/lijst-per-jaar.html?view=publicat [...] Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1805 [article]

Celecoxib for the Treatment of Pain in Osteoarthritis and Rheumatoid Arthritis / Carmen Moga / Alberta [Canada] : Institute of Health Economics (2005)  

Celecoxib for the Treatment of Pain in Osteoarthritis and Rheumatoid Arthritis [printed text] / Carmen Moga, Author ; Christa Harstall, Author ; Zhiliu Tang, Author . - Alberta [Canada] : Institute of Health Economics, 2005 . - viii, 72 p. : ill. ; A4. - (Information Paper, ISSN 1706-7863; 24) . ISSN : 1-894827-12-5 : 0 € Languages : English (eng) Descriptors: Indexation Anti-Inflammatory Agents, Non-Steroidal ; Arthritis, Rheumatoid ; drug therapy ; Therapeutics Classification WB 330 Drug therapy Abstract: Overall, short-term use of celecoxib was equivalent to non-selective NSAIDs (naproxen and diclofenac) and other COX-2 inhibitors (nimesulide and rofecoxib) and was superior to acetaminophen in reducing pain and improving function for patients with RA and OA. Short-term use of celecoxib was associated with a reduction in rates of gastroduodenal erosions or ulcers compared with those for non-selective NSAIDs (naproxen, ibuprofen, and diclofenac) in patients with RA and OA. Many questions remain to be addressed about the long-term safety of celecoxib compared with non-selective NSAIDs and about the combination treatment of NSAIDs and other types of drugs. Health Canada recommended usage restrictions for Celebrex beginning in April 2005. Celebrex should not be used in patients who have had a heart attack or stroke, serious chest pain related to hearth disease, or congestive heart failure. Celebrex may increase the risk of cardiovascular events in patients with high blood pressure, high cholesterol, diabetes, and smoking. Also, Celebrex should be prescribed and used at the lowest possible dose and for the shortest, necessary period of time. Contents note: ACKNOWLEDGEMENTS . I -- EXECUTIVE SUMMARY . III -- ABBREVIATIONS . V -- SCOPE .1 -- BACKGROUND.2 -- EPIDEMIOLOGICAL AND CLINICAL ASPECTS .3 -- COX-2 INHIBITORS .4 -- EVIDENCE FROM SRS .6 -- Efficacy/effectiveness .8 -- Safety ..8 -- EVIDENCE FROM RCTS .12 -- Efficacy/effectiveness .16 -- Safety .17 -- REGULATION STATUS AND POST-MARKETING DATA.20 -- Health Canada and FDA regulatory status .20 -- Labeling and public health alerts in the United States, Canada, and Australia .21 -- Post-marketing data in Canada .22 -- POSITION PAPERS AND GUIDELINES .24 -- COST AND MARKETING .26 -- DISCUSSION .28 -- SRs on celecoxib .28 -- RCTs on celecoxib .28 -- Future research .29 -- Clinical relevance .30 -- CONCLUSION .33 -- REFERENCES .34 -- APPENDIX A: SEARCH AND METHODOLOGY .41 -- APPENDIX B.1: SYSTEMATIC REVIEWS ON EFFICACY/EFFECTIVENESS AND SAFETY .54 -- APPENDIX B.2: RCTS ON EFFICACY/EFFECTIVENESS AND SAFETY .58 -- APPENDIX C: STUDIES (RCTS) ON CELECOXIB FOR OA AND RA INCLUDED IN THE SYSTEMATIC REVIEWS .62 -- APPENDIX D: QUALITY ASSESSMENT CHECKLIST FOR SYSTEMATIC REVIEWS .66 -- APPENDIX E: EXCLUDED SYSTEMATIC REVIEWS AND RANDOMIZED CONTROLLED STUDIES .71 -- Tables and Figures -- FIGURE 1: NUMBER NEEDED TO HARM (NNH) .32 -- TABLE 1: CYCLO-OXYGENASE SELECTIVITY OF COX-2 SELECTIVE AND NON-SELECTIVE NSAIDS (IN VITRO DETERMINATIONS) .5 -- TABLE 2: SUMMARY OF SYSTEMATIC REVIEWS .7 -- TABLE 3: SUMMARY OF RCTS .13 -- TABLE 4: LICENSURE AND INDICATIONS IN CANADA AND THE UNITED STATES .20 -- TABLE 5: POSITION PAPERS AND GUIDELINES ON THE USE OF COX-2 INHIBITORS FOR RA AND OA .25 -- TABLE A.1: DATABASES AND SEARCH TERMS USED IN THE SEARCH STRATEGY (MARCH 2004) .42 -- TABLE A.2: DATABASES AND SEARCH TERMS USED IN THE UPDATED SEARCH STRATEGY (NOVEMBER 2004) .45 -- TABLE A.3: EFFICACY/EFFECTIVENESS OUTCOME MEASURES .51 -- TABLE A.4: SAFETY OUTCOME MEASURES .52 -- TABLE B.1.1: EFFICACY/EFFECTIVENESS OF CELECOXIB FOR THE TREATMENT OF RA .54 -- TABLE B.1.2: SAFETY OF CELECOXIB FOR THE TREATMENT OF OA AND RA .55 -- TABLE B.2.1: EFFICACY/EFFECTIVENESS AND SAFETY OF CELECOXIB FOR THE TREATMENT OF OA AND RA .58 -- TABLE C.1: STUDIES (RCTS) ON CELECOXIB FOR OA AND RA INCLUDED IN THE SYSTEMATIC REVIEWS .62 -- TABLE D.1: CRITICAL APPRAISAL OF REVIEWS .69 -- TABLE E.1: EXCLUDED SYSTEMATIC REVIEWS .71 -- TABLE E.2: EXCLUDED RANDOMIZED CONTROLLED STUDIES .72 Link for e-copy: http://www.ihe.ca/publications/library/archived/celecoxib-for-the-treatment-of-p [...] Format of e-copy: PDF (553 KB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1761

Copies(1)

Barcode	Call number	Media type	Location	Section	Status
10273-01742	WB 330/MOG	Report	KCE	Library (10.124)	Not for loan

Comment formuler une question pico ? / Ann Van den Bruel in Revue médicale de Liège, 59(2004)11 ([11/01/2004])  

[article] Comment formuler une question pico ? [printed text] / Ann Van den Bruel, Author ; Pierre Chevalier, Author ; E. Vermeire, Author ; Bert Aertgeerts, Author ; F. Buntinx, Author . - 2004 . - 671-675. Languages : French (fre) in Revue médicale de Liège > 59(2004)11 [11/01/2004] . - 671-675 Descriptors: Classification W 1 Serials. Periodicals Indexation Belgium ; Child ; drug therapy ; Evidence-Based Medicine ; Humans ; Infant ; Information Storage and Retrieval ; Journal Article ; Peer Review ; Practice Guideline [Publication type] Abstract: Nous commençons notre série d’articles en abordant une affection couramment rencontrée chez l’enfant en pratique médicale : l’otite moyenne. Sous la pression des parents, des antibiotiques sont souvent prescrits. Le médecin sait que l\'utilité de ce traitement est limitée. Mais il doute : en est-il de même pour un enfant d\'un an et demi ? Pour en être sûr, il va confronter ses connaissances avec ce qui est publié dans la littérature et disponible sur internet. Comment débuter cette recherche ? Dans ce premier article, le médecin découvre comment traduire sa question pratique en une question appelant une réponse, et, ensuite, en une question PICO. Ce dernier aspect permet alors au médecin généraliste de trouver des sources utilisables et pertinentes afin d’apporter une réponse rationnelle et fondée à sa question clinique. Link for e-copy: http://www.rmlg.ulg.ac.be/aboel.php?num_id=1144&langue=FR Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1802 [article]

Cost-effectiveness of Herceptin / Mattias Neyt in International Journal of Technology Assessment in Health Care, 21(2005)1 ([02/09/2005])  

[article] Cost-effectiveness of Herceptin : a standard cost model for breast-cancer treatment in a Belgian university hospital [printed text] / Mattias Neyt , Author ; Johan Albrecht, Author ; B. Clarysse, Author ; V. Cocquyt, Author . - 2005 . - p. 132-137. Languages : English (eng) in International Journal of Technology Assessment in Health Care > 21(2005)1 [02/09/2005] . - p. 132-137 Descriptors: Classification W 1 Serials. Periodicals Indexation Antibodies, Monoclonal ; Antineoplastic Agents ; Belgium ; Breast Neoplasms ; drug therapy ; Journal Article ; Peer Review ; Technology Assessment, Biomedical ; therapeutic use Abstract: OBJECTIVES: The objective of this study was to conduct a cost-effectiveness analysis of Herceptin from the hospital's point of view. This new biotechnological pharmaceutical is a humanized monoclonal antibody that targets the HER2 receptor, an important anti-cancer target. METHODS: A cost model with standard diagnostic and treatment options for breast cancer was set up for a Belgian university hospital in close collaboration with its specialists. Direct and indirect costs were calculated for each diagnostic and treatment option using the micro-costing method. Effectiveness was estimated through a literature study. The model allowed us to take cost consequences in other stages of the model into account and to calculate changes in monthly treatment costs from different "starting points." With an incremental cost-effectiveness analysis, differences in costs and effectiveness with and without Herceptin were compared. RESULTS: Over the complete treatment period from diagnosis until the metastatic phase, monthly costs for the hospital rose from 85.07 Euros to 90.35 Euros for stage I diagnosed breast cancer when adding Herceptin to the model. In the metastatic phase alone, these costs rose from 1,132.33 Euros to 1,256.23 Euros. With Herceptin, we found an extra cost of 3,981.44 Euros per extra life-month. CONCLUSIONS: This cost-effectiveness ratio was rather high, because Herceptin was quite expensive and the product was additive in its current use and did not replace existing treatments. Future research will concentrate on alternative applications of Herceptin based on ongoing Herceptin trials and expert opinions. Link for e-copy: https://doi.org/10.1017/S0266462305050178 Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4110 [article]

Current medical research and opinion / Dimitri P. Mikhailidis / London [UK] : Informa Healthcare (1972)  

Permalink

Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda / T. Delvaux in Journal of acquired immune deficiency syndromes, 50(2009)2 ([02/01/2009])  

Permalink

Drug-eluting stents for the treatment of coronary artery disease / ECRI Health Technology Assessment Information Service. / ECRI (2006)  

Permalink

Dual Diagnosis / Giuseppe Carrà / Montrouge [France] : John Libey Eurotext

Permalink

Goodman&Gilman's the pharmacological basis of therapeutics / Louis Sanford Goodman / New York : McGraw-Hill (cop. 2006)

Permalink

Is oraal sumatriptan in lage dosis even effectief als de standaarddosis in de behandeling van migraine? / Ann Van den Bruel in Huisarts Nu, 33(2004)02 ([03/01/2004])  

Permalink

Issues surrounding orphan disease and orphan drug policies in Europe / Alain Denis in Applied Health Economics and Health Policy, 8(2010)5 ([09/01/2010])  

Permalink

Measuring appropriate use of antibiotics in pyelonephritis in Belgian hospitals / Cécile Camberlin in Computer methods and programs in biomedicine, 94(2009)2 ([05/01/2009])  

Permalink

Les médicaments psychiatriques démystifiés / David Healy / Issy les Moulineaux [France] : Elsevier|Masson (2009)

Permalink

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer / Ignace Vergote in The New England journal of medicine, 363(2010)10 ([09/02/2010])  

Permalink